相关实验视频

Updated: Jan 31, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

3.3K

传统与先进的成像选择用于基底动脉阻塞中风的内血管治疗

Huanwen Chen1,2, Marco Colasurdo3, Hidetoshi Matsukawa4

  • 1National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.

European stroke journal
|January 30, 2026
PubMed
概括

传统的成像足以为基础动脉封闭 (BAO) 内血管血栓切除 (EVT) 选择患者. 先进的成像在这个患者群体中没有显示改善的结果.

关键词:
这是一个方面.一个基本的基音.计算机断层扫描 (CT) 是一种计算机断层扫描.发生出血 发生出血影像成像技术 影像成像技术磁共振是一种磁共振.perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion perfusion 这种方法通常被认为是最常见的方法之一,它可以被认为是最常见的方法之一,它可以被认为是最常见的方法之一,它可以被认为是最重要的方法之一.一次性中风中风中风中风中风进行血栓切除术 (thrombectomy).时间窗口时间窗口.

更多相关视频

Author Spotlight: Assessing Ischemic Stroke Damage Through Middle Cerebral Artery Occlusion Model05:32

Author Spotlight: Assessing Ischemic Stroke Damage Through Middle Cerebral Artery Occlusion Model

Published on: August 11, 2023

3.0K
Focal Cerebral Ischemia Model by Endovascular Suture Occlusion of the Middle Cerebral Artery in the Rat13:50

Focal Cerebral Ischemia Model by Endovascular Suture Occlusion of the Middle Cerebral Artery in the Rat

Published on: February 5, 2011

80.9K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
600
Sign Convention01:30

Sign Convention

When analyzing a beam subjected to various loads, it is crucial to understand the internal forces and moments generated within the structure. These internal forces can be broadly classified into normal forces, shear forces, and bending moments. To determine these forces and moments, we use the method of sections and apply a specific sign convention based on their direction and the side of the section being analyzed.
The normal force acts perpendicular to the beam's cross-section and can...
3.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
507
Enolate Mechanism Conventions01:15

Enolate Mechanism Conventions

When a carbonyl compound is treated with a strong base, the α position gets deprotonated to give a resonance-stabilized intermediate called an enolate. Enolates are ambident nucleophiles because they possess two nucleophilic sites that can attack an electrophile owing to the delocalization of the negative charge between the α carbon and oxygen atoms. When the oxygen atom attacks an electrophile, it is called O-attack, whereas electrophilic attack via the α carbon is known as...
2.9K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
616